Tags : Updated

Incyte Reports Updated Results of Pemigatinib in P-II FIGHT-202 Trial

Shots: The P-II FIGHT-202 (NCT02924376) study involves assessing of pemigatinib (13.5 mg, qd) as monothx in adults patients previously treated, LA or metastatic cholangiocarcinoma with documented FGF/FGFR status divided into 3 cohorts: Cohort A (N=107, FGFR2 fusions or rearrangements), Cohort B (N=20, other FGF/FGFR genetic alterations) or Cohort C (N=18, no FGF/FGFR genetic alterations)   […]Read More

Conglomerate of Rheumatology and Spondylitis Organizations Released New Updated Guidelines

The new updated guidelines are being built on previous recommendations based on best practices for imaging, managing biologic and biosimilars usage in patients, and providing information on new medication The guidelines included 20 clinical questions based on pharmacological treatment indicated in 2015 guidelines and 26 new question on the pharmacological treatment treat-to-target strategy, and use […]Read More

Celltrion and Teva Report Results Updated Results of CT-P6 in

Shots: The study involves assessing of CT-P6 vs reference trastuzumab in 516 patients neoadjuvant period of the study entered the adjuvant treatment period The study resulted in 9 patients (3.3%) in the biosimilar group and 6 patients (2.2%) in the reference group in the ITT population had recurrent or progressive disease @1 year. In adjuvant […]Read More

Gilead Reports Updated Results of Descovy in P-III DISCOVER Study

Shots: The P-III DISCOVER study involves assessing of Descovy (emtricitabine, 200 mg/tenofovir alafenamide, 25 mg, qd) vs Truvada (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in adult male and transgender female with HIV PrEP The P-III DISCOVER study results: met its 1EPs of non-inferiority, reduction in time to achieve EC90 of tenofovir diphosphate (TFV-DP) in […]Read More

Roche Reports Updated Results of Hemlibra (emicizumab) in P-III HAVEN

Shots: The P-III HAVEN (1,2,3, & 4) studies involve assessing of Hemlibra in patients with hemophilia A with/out factor VIII inhibitors resulted in zero treat bleeds @83wks., 87% with no treated joint bleeds, 92% with no spontaneous bleeds @25wks., improvement in QoL The P-IIIb STASEY study reinforces safety profile of Hemlibra in 88 patients with […]Read More

Takeda Reports Updated Results of Adynovate in P-IIIb/IV PROPEL Study

Shots: The P-IIIb/IV PROPEL study involves assessing of Adynovate in prophylaxis targeting two different FVIII trough levels (1–3% REF/ 8–12% ELE) in prior treated patients with severe hemophilia A The P-IIIb/IV PROPEL study resulted in enhancing a patient’s PK profile by targeting ELE vs REF, patients with zero bleed (62% vs % vs 42%), reduction […]Read More

BeiGene Reports Updated Results of Tislelizumab in P-II Study in

Shots: The P-II (NCT03209973) study result involves assessing of tislelizumab (200mg, IV, q3w) as a monothx. in 70 patients with R/R to autologous stem cell transplantation (ASCT) or 2L+ r/r cHL The P-II study results: high anti-tumor activity in patients; ORR (87.1%); CR (62.9%); PR (24.3%); @12mos. PFS (73.8%); well tolerated; presented at 24thCongress of […]Read More

Merck Reports Updated Results of Keytruda (pembrolizumab) in P-III KEYNOTE-062

Shots: The P-III KEYNOTE-062 (NCT02494583) study involves assessing of Keytruda as monothx. and in combination with CT (cisplatin/5-fluorouracil/capecitabine) & CT as monthx. in 763 patients for the 1L treatment of advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma The P-III KEYNOTE-062 results: as monothx. met its 1EPs, noninferior to CT; as a combination therapy, no superiority […]Read More